Anavo Therapeutics

Anavo Therapeutics is the first company to systematically develop phosphatase-targeting drugs, a rich target space that has been undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to fully unlock the potential of allosteric modulators targeting phosphatases. In oncology, Anavo is advancing multiple first-in-class therapeutic programs and will establish partnerships on its platform to build a robust pipeline covering a wide range of indications.